NCT04997096 Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
| NCT ID | NCT04997096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-04-02 |
| Primary Completion | 2029-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2022-04-02 with a primary completion date of 2029-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed patients with stages III-IV ovarian or endometrial cancer * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * Physician's clearance to participate in moderate-vigorous intensity exercise * Able to read, write, and understand English * Ability to understand and the willingness to sign an informed consent document * Willing to undergo two venous blood draws for the study Exclusion Criteria: * Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist * Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist * Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for
Frequently Asked Questions
Who can join the NCT04997096 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04997096 currently recruiting?
Yes, NCT04997096 is actively recruiting participants. Visit ClinicalTrials.gov or contact Dana-Farber Cancer Institute to inquire about joining.
Where is the NCT04997096 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT04997096 clinical trial?
NCT04997096 is sponsored by Dana-Farber Cancer Institute. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.